Parenteral Nutrition in Cancer Patients Undergoing Chemotherapy (DRAFT)

2018 ◽  
Author(s):  
Francisco Loaiciga ◽  
Rony Dev
Keyword(s):  
Parenteral Nutrition ◽  
Cancer Patients ◽  
Nutritional Support ◽  
Clinical Case ◽  
Detrimental Effect ◽  
Tumor Response ◽  
Meta Analysis ◽  
Infection Risk ◽  
Gastrointestinal Toxicity ◽  
Patients With Cancer

The meta-analysis by McGeer investigates the benefits of parenteral nutritional support for patients with cancer undergoing chemotherapy. The study concluded that total parenteral nutrition (TPN) has a detrimental effect (decreased survival and poorer tumor response), with an increased infection risk but no significant effect on hematologic or gastrointestinal toxicity. The authors report a net harm with the use of TPN in patients undergoing chemotherapy and recommend that such interventions should be discouraged. This chapter describes the basics of the study, briefly reviews other relevant studies and information, gives a summary and discusses implications, and concludes with a relevant clinical case.

Thrombosis in Cancer Patients Treated with Hematopoietic Growth Factors - A Meta-Analysis

1996 ◽  
Vol 75 (02) ◽  
pp. 368-371 ◽  
Author(s):  
T Barbul ◽  
G Finazzi ◽  
A Grassi ◽  
R Marchioli
Keyword(s):  
Cancer Patients ◽  
Case Reports ◽  
Meta Analysis ◽  
Case Series ◽  
Hematopoietic Growth Factors ◽  
Patients With Cancer ◽  
Cytotoxic Treatment ◽  
Pertinent Data ◽  
Thrombotic Complications ◽  
Vascular Occlusions

SummaryHematopoietic colony-stimulating factors (CSFs) are largely used in patients with cancer undergoing cytotoxic treatment to accelerate neutrophil recovery and decrease the incidence of febrile neutropenia. Clinical practice guidelines for their use have been recently established (1), taking into account clinical benefit, but also cost and toxicity. Vascular occlusions have been recently reported among the severe reactions associated with the use of CSFs, in anedoctal case reports (2, 3), consecutive case series (4) and randomized clinical trial (5, 6). However, the role of CSFs in the pathogenesis of thrombotic complications is difficult to ascertain, because pertinent data are scanty and widely distributed over a number of heterogenous investigations. We report here a systematic review of relevant articles, with the aims to estimate the prevalence of thrombosis associated with the use of CSFs and to assess if this rate is significantly higher than that observed in cancer patients not receiving CSFs.

Effects of nutritional support on the clinical outcomes of well-nourished patients with cancer: a meta-analysis

2020 ◽  
Vol 74 (10) ◽  
pp. 1389-1400
Author(s):  
Xingxia Zhang ◽  
Xinrong Chen ◽  
Jie Yang ◽  
Yanjie Hu ◽  
Ka Li
Keyword(s):  
Clinical Outcomes ◽  
Nutritional Support ◽  
Meta Analysis ◽  
Patients With Cancer

scholarly journals Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 9 (5) ◽  
pp. 1458 ◽  
Author(s):  
Fausto Petrelli ◽  
Alessandro Iaculli ◽  
Diego Signorelli ◽  
Antonio Ghidini ◽  
Lorenzo Dottorini ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Checkpoint Inhibitors ◽  
Meta Analysis ◽  
Progression Free Survival ◽  
Cochrane Library ◽  
Free Survival ◽  
Patients With Cancer ◽  
Hazard Ratios ◽  
The Cochrane Library ◽  
Reporting Data

Antibiotics (ABs) are common medications used for treating infections. In cancer patients treated with immune checkpoint inhibitors (ICIs), concomitant exposure to ABs may impair the efficacy of ICIs and lead to a poorer outcome compared to AB non-users. We report here the results of a meta-analysis evaluating the effects of ABs on the outcome of patients with solid tumours treated with ICIs. PubMed, the Cochrane Library and Embase were searched from inception until September 2019 for observational or prospective studies reporting the prognoses of adult patients with cancer treated with ICIs and with or without ABs. Overall survival (OS) was the primary endpoint, and progression-free survival (PFS) was the secondary endpoint. The effect size was reported as hazard ratios (HRs) with a 95% confidence interval (CI) and an HR > 1 associated with a worse outcome in ABs users compared to AB non-users. Fifteen publications were retrieved for a total of 2363 patients. In the main analysis (n = 15 studies reporting data), OS was reduced in patients exposed to ABs before or during treatment with ICIs (HR = 2.07, 95%CI 1.51–2.84; p < 0.01). Similarly, PFS was inferior in AB users in n = 13 studies with data available (HR = 1.53, 95%CI 1.22–1.93; p < 0.01). In cancer patients treated with ICIs, AB use significantly reduced OS and PFS. Short duration/course of ABs may be considered in clinical situations in which they are strictly needed.

Nutritional support and parenteral nutrition in cancer patients: An expert consensus report

2018 ◽  
Vol 65 ◽  
pp. 17-23 ◽  
Author(s):  
María Julia Ocón Bretón ◽  
Luis Miguel Luengo Pérez ◽  
Juan Antonio Virizuela ◽  
Julia Álvarez Hernández ◽  
Paula Jiménez Fonseca ◽  
...  
Keyword(s):  
Parenteral Nutrition ◽  
Cancer Patients ◽  
Nutritional Support ◽  
Expert Consensus ◽  
Consensus Report

scholarly journals FGFR4 Gly388Arg Polymorphism Reveals a Poor Prognosis, Especially in Asian Cancer Patients: A Meta-Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Jung Han Kim ◽  
Soo Young Jeong ◽  
Hyun Joo Jang ◽  
Sung Taek Park ◽  
Hyeong Su Kim
Keyword(s):  
Cancer Patients ◽  
Transmembrane Domain ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Disease Stage ◽  
Prognostic Impact ◽  
Free Survival ◽  
Patients With Cancer ◽  
Ovid Medline ◽  
Hazard Ratios

The fibroblast growth factor-4 receptor (FGFR4) is a member of receptor tyrosine kinase. The FGFR4 Gly388Arg polymorphism in the transmembrane domain of the receptor has been shown to increase genetic susceptibility to cancers. However, its prognostic impact in cancer patients still remains controversial. Herein, we performed this meta-analysis to evaluate the clinicopathological and prognostic impacts of the FGFR4 Gly388Arg polymorphism in patients with cancer. We carried out a computerized extensive search using PubMed, Medline, and Ovid Medline databases up to July 2021. From 44 studies, 11,574 patients were included in the current meta-analysis. Regardless of the genetic models, there was no significant correlation of the FGFR4 Gly388Arg polymorphism with disease stage 3/4. In the homozygous model (Arg/Arg vs. Gly/Gly), the Arg/Arg genotype tended to show higher rate of lymph node metastasis compared with the Gly/Gly genotype (odds ratio = 1.21, 95% confidence interval (CI): 0.99-1.49, p = 0.06). Compared to patients with the Arg/Gly or Arg/Arg genotype, those with the Gly/Gly genotype had significantly better overall survival (hazard ratios (HR) = 1.19, 95% CI: 1.05-1.35, p = 0.006) and disease-free survival (HR = 1.25, 95% CI: 1.03-1.53, p = 0.02). In conclusion, this meta-analysis showed that the FGFR4 Gly388Arg polymorphism was significantly associated with worse prognosis in cancer patients. Our results suggest that this polymorphism may be a valuable genetic marker to identify patients at higher risk of recurrence or mortality.

scholarly journals POSSIBILITIES OF NUTRITIONAL SUPPORT WITH PROBIOTIC «BIOVESTIN» IN THE FIGHT WITH GASTROINTESTINAL COMPLICATIONS IN CANCER PATIENTS DURING CHEMOTHERAPY

2021 ◽  
pp. 46-50
Author(s):  
V.E. Voitsitsky ◽  
◽  
V.A. Lebedeva ◽  
O.A. Tkachuk ◽  
I.V. Skuridina ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Nutritional Support ◽  
Locally Advanced ◽  
Gastrointestinal Toxicity ◽  
Gastrointestinal Disorders ◽  
Control Group ◽  
Gastrointestinal Complications ◽  
The World ◽  
Oncological Pathology

The incidence of oncological pathology in Russia and throughout the world is steadily growing, and the mortality rate is not decreasing either. A large number of locally advanced and neglected cases of cancer of various location are revealed. Treatment of these forms requires polychemotherapy (PCT). The study included 52 patients with oncological pathology of various location: head and neck, stomach, large intestine, they underwent adjuvant chemotherapy according to the PF, TPF and FOLFOX regimens, which include an infusion of 5-fluorouracil for 2–5 days. The study analyzed gastrointestinal toxicity according to CTCAE, version 4.03, 2010. It was revealed that the addition of the probiotic Biovestin to meal reduces gastrointestinal toxicity by 2 times compared with the control group and reduces the risk of interruption of the PCT course by 19 % due to the development of side effects. Thus, the addition of the probiotic Biovestin has shown its effectiveness, safety and simplicity of use in the prevention of gastrointestinal disorders in cancer patients under conditions of PCT.

scholarly journals The impact of informing diagnosis on quality of life in patients with cancer: A systematic review and meta-analysis

2020 ◽  
Author(s):  
Miao Wan ◽  
Xianggui Luo ◽  
Louis.B NDZANA MVOGO ◽  
Juan Wang ◽  
Chen Chang ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Cognitive Activity ◽  
Biomedical Literature ◽  
Cochrane Central Register ◽  
Patients With Cancer ◽  
General Quality ◽  
The Impact

Abstract Objective To assess the impact of informing diagnosis and disease status on the quality of life in patients with cancer Method We searched the follow databases, Pubmed, CENTRAL(Cochrane Central Register of Controlled Trials), PsycINFO, WEB OF SCIENCE, Embase, CBM (Chinese Biomedical Literature database), WANFANG database (Chinese Medicine Premier), and CNKI (China National Knowledge Infrastructure). And the terms used are as follows: neoplasm, cancer, tumour, tumor, carcinoma, disclosure, truth telling, breaking bad news, knowledge, knowing, awareness, quality of life, QOL. Pairs of reviewers independently screened documents and extracted the data. Meta-analysis was conducted by Revman 5.0 software. Results There were 11740 records retrieved from databases and 23 studies were included finally. Meta-analysis of informed and uniformed cancer patients revealed no differences in both the general quality of life and symptoms of fatigue, pain, dyspnea, insomnia, appetite loss and diarrhea (P>0.05). Additionally, no difference in physical function, role function, cognitive activity and emotional function between the above 2 groups(P>0.05) were found. On the vitality area, the patients who were totally informed about their diagnosis had higher vitality than the uniformed patients. However, patients aware about their illnesses seemed to get lower scores in social function. Between the partly informed of the diagnosis and uninformed cancer patients, there were no differences in general quality of life, function domains and disease-related symptoms (P>0.05). Conclusion Informing the cancer patients their diagnosis may not have a bad effect on their quality of life. PROSPERO registration number CRD42017060073.

scholarly journals Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis

2020 ◽  
Author(s):  
Fausto Petrelli ◽  
Alessandro Iaculli ◽  
Diego Signorelli ◽  
Antonio Ghidini ◽  
Lorenzo Dottorini ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Checkpoint Inhibitors ◽  
Meta Analysis ◽  
Progression Free Survival ◽  
Cochrane Library ◽  
Free Survival ◽  
Patients With Cancer ◽  
Hazard Ratios ◽  
The Cochrane Library ◽  
Reporting Data

Antibiotics (ABs) are common medications used for treating infections. In cancer patients treated with immune checkpoint inhibitors (ICIs), concomitant exposure to ABs may impair the efficacy of ICIs and lead to a poorer outcome compared to AB non-users. We report here the results of a meta-analysis evaluating the effects of ABs on the outcome of patients with solid tumors treated with ICIs. PubMed, the Cochrane Library, and Embase were searched from inception until September 2019 for observational or prospective studies reporting prognosis of adult patients with cancer treated with ICIs and with or without ABs. Overall survival (OS) was the primary endpoint, and progression-free survival (PFS) was the secondary endpoint. The effect size was reported as hazard ratios (HRs) with a 95% confidence interval (CI), and an HR &gt; 1 associated with a worse outcome in ABs users compared to no-ABs users. Fifteen publications were retrieved for a total of 2363 patients. In the main analysis (n = 15 studies reporting data), OS was reduced in patients exposed to ABs before or during treatment with ICIs (HR = 2.07, 95%CI 1.51&ndash;2.84; P&lt;.01). Similarly, PFS was inferior in ABs users in n = 13 studies with data available (HR = 1.53, 95%CI 1.22&ndash;1.93; p&lt;.01). In cancer patients treated with ICIs, AB use significantly reduces OS and PFS. Short duration/course of ABs may be considered in clinical situations in which they are strictly needed.

Sign in / Sign up

Export Citation Format

Share Document